Outpatient Antipsychotic Use and Severe COVID-19: Avoiding the Impact of Age in a Real-World Data Study
- PMID: 38600711
- PMCID: PMC11059787
- DOI: 10.1093/ijnp/pyae020
Outpatient Antipsychotic Use and Severe COVID-19: Avoiding the Impact of Age in a Real-World Data Study
Abstract
Background: The association between use of antipsychotics and COVID-19 outcomes is inconsistent, which may be linked to use of these drugs in age-related diseases. Furthermore, there is little evidence regarding their effect in the nongeriatric population. We aim to assess the association between antipsychotic use and risk of disease progression and hospitalization due to COVID-19 among the general population, stratifying by age.
Methods: We conducted a population-based, multiple case-control study to assess risk of hospitalization, with cases being patients with a PCR(+) test who required hospitalization and controls being individuals without a PCR(+) test; and risk of progression to hospitalization, with cases being the same as those used in the hospitalization substudy and controls being nonhospitalized PCR(+) patients. We calculated adjusted odds-ratios (aOR) and 95% confidence intervals (CI), both overall and stratified by age.
Results: Antipsychotic treatment in patients younger than 65 years was not associated with a higher risk of hospitalization due to COVID-19 (aOR 0.94 [95%CI = 0.69-1.27]) and disease progression among PCR(+) patients (aOR 0.96 [95%CI = 0.70-1.33]). For patients aged 65 years or older, however, there was a significant, increased risk of hospitalization (aOR 1.58 [95% CI = 1.38-1.80]) and disease progression (aOR 1.31 [95% CI = 1.12-1.55]).
Conclusions: The results of our large-scale real-world data study suggest that antipsychotic use is not associated with a greater risk of hospitalization due to COVID-19 and progression to hospitalization among patients younger than 65 years. The effect found in the group aged 65 years or older might be associated with off-label use of antipsychotics.
Keywords: Antipsychotics; COVID-19; age; hospitalization; real-world data.
© The Author(s) 2024. Published by Oxford University Press on behalf of CINP.
Similar articles
-
Prescription of Controlled Substances: Benefits and Risks.2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2025 Jul 6. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 30726003 Free Books & Documents.
-
Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception.Cochrane Database Syst Rev. 2023 Jan 9;1(1):CD014908. doi: 10.1002/14651858.CD014908.pub2. Cochrane Database Syst Rev. 2023. Update in: Cochrane Database Syst Rev. 2023 May 15;5:CD014908. doi: 10.1002/14651858.CD014908.pub3. PMID: 36622724 Free PMC article. Updated.
-
Sertindole for schizophrenia.Cochrane Database Syst Rev. 2005 Jul 20;2005(3):CD001715. doi: 10.1002/14651858.CD001715.pub2. Cochrane Database Syst Rev. 2005. PMID: 16034864 Free PMC article.
-
Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007726. doi: 10.1002/14651858.CD007726.pub2. Cochrane Database Syst Rev. 2013. PMID: 23543555
-
Atypical antipsychotics for disruptive behaviour disorders in children and youths.Cochrane Database Syst Rev. 2017 Aug 9;8(8):CD008559. doi: 10.1002/14651858.CD008559.pub3. Cochrane Database Syst Rev. 2017. PMID: 28791693 Free PMC article.
Cited by
-
Antipsychotics, COVID-19, and Secondary Healthcare Databases: Revisiting the Pandemic.Int J Neuropsychopharmacol. 2024 Jul 1;27(7):pyae026. doi: 10.1093/ijnp/pyae026. Int J Neuropsychopharmacol. 2024. PMID: 38878266 Free PMC article. No abstract available.
References
-
- Bliek-Bueno K, Mucherino S, Poblador-Plou B, González-Rubio F, Aza-Pascual-Salcedo M, Orlando V, Clerencia-Sierra M, Ioakeim-Skoufa I, Coscioni E, Carmona-Pírez J, Perrella A, Trama U, Prados-Torres A, Menditto E, Gimeno-Miguel A (2021) Baseline drug treatments as indicators of increased risk of COVID-19 mortality in Spain and Italy. Int J Environ Res Public Health 18:11786. - PMC - PubMed
-
- Bonanad C, García-Blas S, Tarazona-Santabalbina FJ, Díez-Villanueva P, Ayesta A, Sanchis Forés J, Vidán-Austiz MT, Formiga F, Ariza-Solé A, Martínez-Sellés M; Scientific societies of the authors. The contributing authors are members of the following scientific bodies (2020) Coronavirus: la emergencia geriátrica de 2020. Documento conjunto de la Sección de Cardiología Geriátrica de la Sociedad Española de Cardiología y la Sociedad Española de Geriatría y Gerontología. Rev Esp Cardiol 73:569–576. - PMC - PubMed
-
- Canal-Rivero M, Catalán-Barragán R, Rubio-García A, Garrido-Torres N, Crespo-Facorro B, Ruiz-Veguilla M; IBIS Translational Psychiatry Group (2021) Lower risk of SARS-CoV2 infection in individuals with severe mental disorders on antipsychotic treatment: a retrospective epidemiological study in a representative Spanish population. Schizophr Res 229:53–54. - PMC - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical